8 Biotechnology Stocks to Buy Now

EPZM, STML, PCYC, ACOR, NWBO, BMRN, SGEN, AMGN improve in weekly rankings

   
8 Biotechnology Stocks to Buy Now

This week, eight biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

Epizyme, Inc. (EPZM) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. In Portfolio Grader’s specific subcategories of Earnings Momentum and Sales Growth, EPZM also gets A’s. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of EPZM stock.

Stemline Therapeutics, Inc. (STML) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Shares of the stock have been trading at an exceptionally rapid pace, up threefold from the week prior. For more information, get Portfolio Grader’s complete analysis of STML stock.

Pharmacyclics, Inc. (PCYC) gets a higher grade this week, advancing from a C last week to a B. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. Shares of the stock have been changing hands at an unusually rapid pace, three times the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of PCYC stock.

This week, Acorda Therapeutics, Inc.’s (ACOR) ratings are up from a C last week to a B. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of ACOR stock.

Northwest Biotherapeutics, Inc.’s (NWBO) ratings are looking better this week, moving up to a B from last week’s C. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of NWBO stock.

BioMarin Pharmaceutical (BMRN) improves from a C to a B rating this week. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. Shares of the stock have been trading at an exceptionally rapid pace, up threefold from the week prior. For more information, get Portfolio Grader’s complete analysis of BMRN stock.

This is a strong week for Seattle Genetics, Inc. (SGEN). The company’s rating climbs to B from the previous week’s C. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of SGEN stock.

The rating of Amgen (AMGN) moves up this week, rising from a B to an A. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. At present, the stock has a dividend yield of 2.4%. For more information, get Portfolio Grader’s complete analysis of AMGN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2014/07/8-biotechnology-stocks-to-buy-now-epzm-stml-pcyc/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.